Positive News SentimentPositive NewsNYSE:PEN Penumbra (PEN) Stock Price, News & Analysis $328.46 -0.24 (-0.07%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$328.68 +0.23 (+0.07%) As of 05/22/2026 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Penumbra Stock (NYSE:PEN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Penumbra alerts:Sign Up Key Stats Today's Range$327.92▼$329.6750-Day Range$321.64▼$338.6552-Week Range$221.26▼$362.41Volume508,515 shsAverage Volume435,224 shsMarket Capitalization$12.92 billionP/E Ratio75.68Dividend YieldN/APrice Target$361.33Consensus RatingHold Company Overview Penumbra, Inc. is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world. At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases. The company also offers embolization coil systems and flow-diversion devices for the treatment of cerebral aneurysms and vascular lesions. In its peripheral vascular line, Penumbra markets aspiration thrombectomy systems and small-vessel clot retrieval tools designed for limb salvage and treatment of pulmonary embolism. Founded in 2004 by engineer Arani Bose, Penumbra launched its first commercial thrombectomy product in 2007 and has since expanded into new geographies and indications. The company maintains its headquarters in Alameda, California, with additional operations in Europe and Asia Pacific. Over the years, Penumbra has invested in R&D facilities and regulatory approvals to support product launches across more than 100 countries. Under the leadership of President and Chief Executive Officer Adam Elsesser, Penumbra continues to advance its pipeline of next-generation devices, focusing on catheter design, clot visualization and real-time feedback technologies. The company collaborates with academic institutions and clinical specialists to refine procedural techniques and drive evidence generation in stroke and vascular care.AI Generated. May Contain Errors. Read More Penumbra Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScorePEN MarketRank™: Penumbra scored higher than 72% of companies evaluated by MarketBeat, and ranked 201st out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingHold Consensus RatingPenumbra has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on no strong buy ratings, 3 buy ratings, 14 hold ratings, and no sell ratings.Upside PotentialPenumbra has a consensus price target of $361.33, representing about 10.0% upside from its current price of $328.46.Amount of Analyst CoveragePenumbra has only been the subject of 3 research reports in the past 90 days.Read more about Penumbra's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth26.57% Earnings GrowthEarnings for Penumbra are expected to grow by 26.57% in the coming year, from $5.08 to $6.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Penumbra is 75.68, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Penumbra is 75.68, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.26.Price to Earnings Growth RatioPenumbra has a PEG Ratio of 2.01. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioPenumbra has a P/B Ratio of 8.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Penumbra's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.97% of the float of Penumbra has been sold short.Short Interest Ratio / Days to CoverPenumbra has a short interest ratio ("days to cover") of 3.28, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Penumbra has recently decreased by 5.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPenumbra does not currently pay a dividend.Dividend GrowthPenumbra does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment1.76 News SentimentPenumbra has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Penumbra this week, compared to 5 articles on an average week.Search Interest2 people have searched for PEN on MarketBeat in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $865,296.00 in company stock.Percentage Held by Insiders2.90% of the stock of Penumbra is held by insiders.Percentage Held by Institutions88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Penumbra's insider trading history. Receive PEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PEN Stock News HeadlinesAssessing Penumbra (PEN) Valuation As Growth Expectations Meet A Premium P/E MultipleMay 7, 2026 | finance.yahoo.comPenumbra: Q1 Earnings SnapshotMay 6, 2026 | chron.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Penumbra, Inc. Reports First Quarter 2026 Financial ResultsMay 6, 2026 | prnewswire.comInside Boston Scientific's $15 billion offer for Alameda's largest employerMay 2, 2026 | bizjournals.comRBC Capital Remains a Hold on Penumbra (PEN)April 17, 2026 | theglobeandmail.comNew STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism PatientsApril 13, 2026 | prnewswire.comPenumbra Sale To Boston Scientific Sparks Review Of Deal ValueApril 10, 2026 | finance.yahoo.comSee More Headlines PEN Stock Analysis - Frequently Asked Questions How have PEN shares performed this year? Penumbra's stock was trading at $311.45 at the start of the year. Since then, PEN stock has increased by 5.5% and is now trading at $328.4550. How were Penumbra's earnings last quarter? Penumbra, Inc. (NYSE:PEN) issued its quarterly earnings results on Wednesday, May, 6th. The company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.06 by $0.24. The business's revenue was up 15.6% compared to the same quarter last year. How will Penumbra's stock buyback program work? Penumbra's board initiated a stock repurchase program on Tuesday, August 13th 2024, which allows the company to repurchase $200,000,000 in shares, according to EventVestor. This means that the company could buy up to 2.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its shares are undervalued. When did Penumbra IPO? Penumbra (PEN) raised $106 million in an initial public offering (IPO) on Friday, September 18th 2015. The company issued 4,000,000 shares at $25.00-$28.00 per share. Who are Penumbra's major shareholders? Top institutional investors of Penumbra include Whitebox Advisors LLC (1.13%), Arrowstreet Capital Limited Partnership (1.02%), Amundi (0.88%) and Dimensional Fund Advisors LP (0.83%). Insiders that own company stock include Arani Bose, Adam Elsesser, Johanna Roberts, Lambert Shiu, Maggie Yuen, Harpreet Grewal, Bridget O'rourke, Surbhi Sarna, Don W Kassing and Thomas Wilder. View institutional ownership trends. How do I buy shares of Penumbra? Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Penumbra own? Based on aggregate information from My MarketBeat watchlists, some other companies that Penumbra investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), ServiceNow (NOW), Adobe (ADBE) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/06/2026Today5/24/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PEN's financial health is in the Green zone, according to TradeSmith. PEN has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNYSE:PEN CIK1321732 Webwww.penumbrainc.com Phone(510) 748-3200Fax510-748-3232Employees4,700Year Founded2004Price Target and Rating Average Price Target for Penumbra$361.33 High Price Target$388.00 Low Price Target$266.00 Potential Upside/Downside+10.0%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$4.34 Trailing P/E Ratio75.68 Forward P/E Ratio64.66 P/E Growth2.01Net Income$177.69 million Net Margins11.76% Pretax Margin13.96% Return on Equity10.87% Return on Assets8.45% Debt Debt-to-Equity Ratio0.01 Current Ratio6.02 Quick Ratio3.95 Sales & Book Value Annual Sales$1.40 billion Price / Sales9.20 Cash Flow$4.30 per share Price / Cash Flow76.46 Book Value$37.47 per share Price / Book8.77Miscellaneous Outstanding Shares39,330,000Free Float38,190,000Market Cap$12.92 billion OptionableOptionable Beta0.74 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:PEN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Penumbra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
